Figure 6: Decreased thymic selection of V α 14 NKT cells in CD1-TD mice. In summary, the CD1-TD knock-in mouse showed selective defects in CD1d-mediated antigen presentation. It allowed the ...

12–14 In preclinical models, defects ... PD-1 therapy on cancer genomic evolution, including acquired mutations in the genes affecting the interferon pathway and antigen-presentation pathway ...

Yuan Liu from Georgia State University reports that intratumoral SIRPα-deficient macrophages activate tumor ... excellent antigen presenting cells that conduct immunogenic antigen presentation ...

Deep-learning analysis of H&E images to define three immune phenotypes to reveal loss-of-target in excluded immune cells as a novel resistance mechanism of immune checkpoint inhibitor in non-small ...

Tumor antigens are captured and displayed by antigen processing and presentation machinery (APM) on the cell surface by HLA-I, making it possible for CD8 + T cells to eliminate cancer cells.

(3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to recognize tumor-specific antigens. (4) CAR-T cells are expanded ex vivo to achieve sufficient ...

YTHDF1 controls the level of proteases that destroy potential tumor antigens. This limits their presentation to T cells. These limits were a problem, He said. But when he and his colleagues ...

including those involved in antigen presentation and immune surveillance. Notably, this mechanistic interaction was found to be cell- and cancer-type agnostic, providing a generalized mechanism of ...

CAR+ cells denote CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III (EGFRvIII) tumor-specific ...

“The insertion of the α1,3GT gene into NDV enabled infected tumor cells to express exogenous αGal antigen, eliciting a rapid and robust humoral and cellular immune response,” Dr Zhao’s ...